185 related articles for article (PubMed ID: 14651407)
21. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
Devi KhS; Brajachand N; Singh HL; Singh YM
J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B infection and vaccination among high-risk noninjection drug-using women: baseline data from the UNITY study.
Koblin BA; Xu G; Lucy D; Robertson V; Bonner S; Hoover DR; Fortin P; Latka M
Sex Transm Dis; 2007 Nov; 34(11):917-22. PubMed ID: 17579337
[TBL] [Abstract][Full Text] [Related]
23. Provision of bloodborne virus screening in substance misuse.
Harniman B
Nurs Times; 2006 Aug 1-7; 102(31):28-30. PubMed ID: 16913519
[TBL] [Abstract][Full Text] [Related]
24. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
25. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
[TBL] [Abstract][Full Text] [Related]
26. Gender differences in injection risk behaviors at the first injection episode.
Frajzyngier V; Neaigus A; Gyarmathy VA; Miller M; Friedman SR
Drug Alcohol Depend; 2007 Jul; 89(2-3):145-52. PubMed ID: 17276623
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
28. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program.
Gunn RA; Lee MA; Callahan DB; Gonzales P; Murray PJ; Margolis HS
Am J Prev Med; 2005 Jul; 29(1):27-33. PubMed ID: 15958248
[TBL] [Abstract][Full Text] [Related]
29. Changing prevalence of hepatitis B virus and hepatitis D virus infection among injecting drug users in Hong Kong indicating a change in high-risk behaviour.
Lim WL; Lo JY; Lee SH
AIDS; 1995 Sep; 9(9):1110-2. PubMed ID: 8527093
[No Abstract] [Full Text] [Related]
30. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis.
Rhodes T; Treloar C
Addiction; 2008 Oct; 103(10):1593-603. PubMed ID: 18821870
[TBL] [Abstract][Full Text] [Related]
31. The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia.
Day C; Degenhardt L; Gilmour S; Hall W
BMC Public Health; 2005 Aug; 5():84. PubMed ID: 16102177
[TBL] [Abstract][Full Text] [Related]
32. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices.
Rodríguez-Méndez ML; González-Quintela A; Aguilera A; Carballo E; Barrio E
Hepatogastroenterology; 2003; 50(54):2093-7. PubMed ID: 14696471
[TBL] [Abstract][Full Text] [Related]
33. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y
Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852
[TBL] [Abstract][Full Text] [Related]
35. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003-2005.
Sunthornchart S; Linkins RW; Natephisarnwanish V; Levine WC; Maneesinthu K; Lolekha R; Tappero JW; Trirat N; Muktier S; Chancharastong P; Fox K; Donchalermpak S; Vitek C; Supawitkul S
Addiction; 2008 Oct; 103(10):1687-95. PubMed ID: 18705685
[TBL] [Abstract][Full Text] [Related]
37. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
Vassilev ZP; Hagan H; Lyubenova A; Tomov N; Vasilev G; Krasteva D; Des Jarlais DC
Int J STD AIDS; 2006 Sep; 17(9):621-6. PubMed ID: 16942654
[TBL] [Abstract][Full Text] [Related]
38. Peer-delivered hepatitis C testing and counselling: a means of improving the health of injecting drug users.
Aitken CK; Kerger M; Crofts N
Drug Alcohol Rev; 2002 Mar; 21(1):33-7. PubMed ID: 12189002
[TBL] [Abstract][Full Text] [Related]
39. Circumstances surrounding the first injection experience and their association with future syringe sharing behaviors in young urban injection drug users.
Novelli LA; Sherman SG; Havens JR; Strathdee SA; Sapun M
Drug Alcohol Depend; 2005 Mar; 77(3):303-9. PubMed ID: 15734230
[TBL] [Abstract][Full Text] [Related]
40. Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase.
Copeman M
Med J Aust; 2003 Jul; 179(2):119; author reply 119. PubMed ID: 12864712
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
